Sanofi has launched a €1.10 billion share repurchase program, equivalent to approximately $1.20 billion at current exchange rates, following stronger-than-expected fourth-quarter results. The buyback authorisation covers up to 2.5 percent of outstanding capital and will be executed through on-market purchases over the next 12 months. The repurchase is intended to enhance earnings per share and return surplus cash to shareholders, reflecting Sanofi’s solid balance sheet, which featured net cash of €11.5 billion as of December 31, 2025.

In the fourth quarter, Sanofi reported a 7 percent increase in sales to €12.3 billion, driven by continued momentum in its immunology and rare disease franchises. Revenues from Dupixent rose by 28 percent year-on-year to €2.9 billion, while rare blood disorder drug revenues climbed 15 percent to €1.4 billion. Adjusted operating income improved by 9 percent to €3.8 billion, boosting the company’s adjusted operating margin to 30.9 percent. Strength in emerging markets, which grew 12 percent, also contributed to the quarter’s outperformance.

Sanofi is targeting high-single-digit sales growth in 2026, underpinned by ongoing demand for Dupixent and its next-generation oncology and cardiovascular pipeline candidates. The company plans to invest €600 million in R&D this year, focusing on gene therapy and mRNA platforms. Additionally, Sanofi committed €20 million to Sensorion’s €60 million financing round to advance its genetic medicine pipeline, anchoring the partnership that will support Sensorion’s SENS-601 program through clinical trial application and early patient enrollment.